Month: January 2026

LONGBOAT KEY, FL, Jan. 12, 2026 (GLOBE NEWSWIRE) — Rumble Inc. (NASDAQ:RUM), the Freedom-First technology platform, today announced that it has entered into an exclusive video and live streaming distribution agreement with The Dan Bongino Show. Dan Bongino will return to podcasting with the relaunch of the show beginning February 2, 2026. The agreement grants Rumble exclusive video distribution rights, making it the only platform where audiences can watch the show’s daily live stream. The audio-only version of the program will be available across all major podcast platforms. Westwood One will serve as the exclusive sales partner for The Dan Bongino Show. The relaunch marks Bongino’s most extensive digital commitment to date, designed to meet growing audience demand for long-form and in-depth content. The show will stream weekdays...

(2026-01-12) Reference is made to the stock exchange announcement made by Kitron ASA (the “Company” or “Kitron”) on 19 November 2025 regarding the entering into agreement to, through its subsidiary Kitron Holding AB, acquire DeltaNordic AB (the “Transaction”). As disclosed in the said announcement, the purchase price for the shares in DeltaNordic AB will be partly settled by issuance of SEK 150 million in Kitron shares. In connection with completion of the Transaction, Kitron’s board of directors has today resolved to issue 2,299,612 new shares to the sellers pursuant to the existing board authorisation to issue new shares granted by the Company’s annual general meeting held on 24 April 2025. 1,192,927 of the consideration shares are subject to a lock-up period of 12 months and 1,106,685...

Kfar Saba, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today reflects on a transformative 2025 for its DropAir™ Precision Airdrop System – turning battlefield lessons from recent wars into validated, life-saving technology now expanding to civilian, medical, and humanitarian markets worldwide. In 2025, ParaZero achieved a series of significant milestones that positioned DropAir as a leading solution for precise, no-landing deliveries in high-risk environments:February 2025: Successfully transitioned to Phase II of the DropAir project with the Israeli Ministry of Defense following positive Phase I results, advancing development...

WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial in atopic dermatitis (AD) for ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody. “We are experiencing strong momentum in the ATI-052 clinical development program including the recent positive Phase 1a interim results which demonstrated a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics even at the lowest dose,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris. “Further to this, we are excited to announce the...

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 Preparation of NDA dossier of deucrictibant for on-demand treatment of HAE attacks ongoing; timeline remains on-track for filing in 1H2026 Recruitment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Estimated cash runway into 1H2027ZUG, Switzerland, Jan. 12, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today outlined its strategic priorities for 2026. “The...

For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectively Rare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, unaudited results Provides full year 2026 financial guidance, which includes:Total net revenues of $1,055 million to $1,115 million Cortrophin Gel net revenues of $540 million to $575 million Adjusted non-GAAP EBITDA of $275 million to $290 million Rare Disease business to represent approximately 60% of total net revenuesAnnounces ~90-person expansion of Rare Disease organization...

2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies Expected 2026 oncology milestones include seven late-stage data readouts and to have 15 Phase 3 clinical trials ongoing by year end Additional late-stage trial readouts through 2030+ set to create multiple launch opportunities across tumor types, building BioNTech into a multi-product oncology company Financial strength with €17.2 billion in cash and cash equivalents plus security investments1, COVID-19 vaccine revenue stream, disciplined R&D spend, and strategic partnerships will continue to enable sustainable innovation Presentation and webcast at the 44th Annual J.P. Morgan Healthcare Conference from 2:15 – 2:55 pm PT / 11:15 – 11:55 pm CET on...

Inspire Announces Appointment of Matt Osberg as Executive Vice President and Chief Financial Officer Joining the Company in the First Quarter of 2026 MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025, and provided its initial full year 2026 revenue guidance. Further, the Company announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer. Preliminary, Unaudited Fourth Quarter and Full Year 2025 RevenueRevenue for the fourth quarter of 2025 is anticipated...